Recherche
Résultats 91-100 de 241
-
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
BLOOD ADVANCES, 18-07-2020, 4, 3217-3223Article dans une revue scientifique -
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
BLOOD ADVANCES, 23-03-2021, 5, 1737-1745Article dans une revue scientifique -
Bartonellosis mimicking post-transplant lymphoproliferative diseases.
Nephrol Dial Transplant, 20-11-2021Article dans une revue scientifique -
Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2.
BLOOD ADVANCES, 27-04-2022Article dans une revue scientifique -
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.
Haematologica, 02-06-2022Article dans une revue scientifique -
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet, 23-06-2022, 399, 2294-2308Article dans une revue scientifique -
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R <sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
Journal of clinical oncology, 12-08-2022, JCO2200843Article dans une revue scientifique -
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.
BLOOD ADVANCES, 03-08-2021, 5, 2965-2968Article dans une revue scientifique -
Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.
Br J Haematol, 24-05-2023Article dans une revue scientifique -
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory NHL: A phase IB/II study.
Am J Hematol, 04-11-2021Article dans une revue scientifique